Volume 2, Issue 1 (January 2023)
Health Science Monitor 2023, 2(1): 61-72 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Houshmand H, Jafary R, Rasoli J, Ahmadi A. Investigation of specific antibody titer against SARS-CoV-2 virus during hospitalization and one month after discharge in hospitalized children with severe and critical Covid-19 infection. Health Science Monitor 2023; 2 (1) :61-72
URL: http://hsm.umsu.ac.ir/article-1-76-en.html
URL: http://hsm.umsu.ac.ir/article-1-76-en.html
Assistant Professor of Medical Immunology, Cellular and Molecular Research Center, Cellular and Molecular Medicine Research Institute, Urmia University of Medical Sciences, Urmia, Iran
Abstract: (537 Views)
Background & Aims: The response of the human immune system to the COVID-19 disease is of vital importance in many ways, including determining the place of serological methods in the survival of patients. Therefore, the present study was designed and implemented with the aim of determining the specific antibody titer against SARS CoV-2 during hospitalization and one month after discharge in children hospitalized in Shahid Motahari Hospital in Urmia.
Materials & Methods: In this longitudinal study, hospitalized patients with positive RT-PCR test were included in the study due to COVID-19. Inclusion criteria included age less than 15 years and parental consent, and exclusion criteria included immune system disorder or developmental disorder and negative RT-PCR test. Demographic information and severity of the disease along with specific antibody titer of SARS-CoV-2 were evaluated and extracted for all patients.
Results: The average age of the 40 studied patients was 2.48 years, and 32.5% of them were girls. The average level of IgG during discharge and one month after discharge was equal to 73.66 and 128.36, respectively, and it was significantly higher one month after discharge than during discharge (p<0.001). There was no statistically significant difference between the two sexes in terms of antibody titer during discharge (p=0.77) and one month after discharge (p=0.31). There is no significant relationship between the specific antibody level of SARS-CoV-2 during discharge (r=0.12 and p=0.45) and one month after discharge and length of hospitalization. There was no statistically significant difference between disease severity and antibody titer during discharge (p=0.54) and one month after discharge (p=0.20).
Conclusion: The specific antibody titer of SARS-CoV-2 increases significantly after one month of discharge. There was no significant difference between the level of this antibody during discharge and one month later between girls and boys and people with different severity of the disease. No significant relationship between antibody titer and hospitalization time was observed.
Materials & Methods: In this longitudinal study, hospitalized patients with positive RT-PCR test were included in the study due to COVID-19. Inclusion criteria included age less than 15 years and parental consent, and exclusion criteria included immune system disorder or developmental disorder and negative RT-PCR test. Demographic information and severity of the disease along with specific antibody titer of SARS-CoV-2 were evaluated and extracted for all patients.
Results: The average age of the 40 studied patients was 2.48 years, and 32.5% of them were girls. The average level of IgG during discharge and one month after discharge was equal to 73.66 and 128.36, respectively, and it was significantly higher one month after discharge than during discharge (p<0.001). There was no statistically significant difference between the two sexes in terms of antibody titer during discharge (p=0.77) and one month after discharge (p=0.31). There is no significant relationship between the specific antibody level of SARS-CoV-2 during discharge (r=0.12 and p=0.45) and one month after discharge and length of hospitalization. There was no statistically significant difference between disease severity and antibody titer during discharge (p=0.54) and one month after discharge (p=0.20).
Conclusion: The specific antibody titer of SARS-CoV-2 increases significantly after one month of discharge. There was no significant difference between the level of this antibody during discharge and one month later between girls and boys and people with different severity of the disease. No significant relationship between antibody titer and hospitalization time was observed.
Type of Study: Research |
Subject:
Special
Received: 2022/10/7 | Accepted: 2022/12/21 | Published: 2023/01/20
Received: 2022/10/7 | Accepted: 2022/12/21 | Published: 2023/01/20
References
1. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. Br Med J 2020;368(1123):249-73. [DOI] [PMID] [PMCID]
2. Ye G, Pan Z, Pan Y, Deng Q, Chen L, Li J, et al. Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation. Journal of Infection. 2020;80(5):e14-e7. [DOI] [PMID] [PMCID]
3. Farnoosh G, Alishiri G, Zijoud SH, Dorostkar R, Farahani AJ. Understanding the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease (COVID-19) based on available evidence-a narrative review. Journal of Military Medicine 2020;22(1):1-11. [Google Scholar]
4. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. The New England Journal of Medicine. 2020;72(11):1211-25. [DOI] [PMID] [PMCID]
5. Wang Y, Guo H, Lu Z, et al. Characteristics of patients with coronavirus disease (COVID‐19) confirmed using an IgM‐IgG antibody test. Journal of Medical Virology. 2020;92(10):204-10. [DOI] [PMID] [PMCID]
6. Tavakoli A, Vahdat K, Keshavarz M. Novel coronavirus disease 2019 (COVID-19): an emerging infectious disease in the 21st century. Iranian Sout Medical Journal. 2020;22(6):432-50. [DOI]
7. Chavez S, Long B, Koyfman A, Liang SY. Coronavirus Disease (COVID-19): A primer for emergency physicians. The American Journal of Emergency Medicine. 2020;11(3):371-89. [DOI]
8. Lam TT-Y, Shum MH-H, Zhu H-C, Tong Y-G, Ni X-B, Liao Y-S, et al. Identification of 2019-nCoV related coronaviruses in Malayan pangolins in southern China. BioRxiv. 2020;5(23):148-62. [DOI]
9. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The lancet. 2020;395(10224):565-74. [DOI] [PMID]
10. Control CfD, Prevention. Coronavirus Disease 2019: COVID-19. 2020;13(2):28-48.
11. Ahmad I, Rathore FA. Neurological manifestations and complications of COVID-19: A literature review. Journal of Clinical Neuroscience. 2020;341(38):189-201.
https://doi.org/10.20944/preprints202004.0453.v1 [DOI]
12. Combes AJ, Courau T, Kuhn NF, Hu KH, Ray A, Chen WS, et al. Global absence and targeting of protective immune states in severe COVID-19. Nature. 2021;591(7848):124-30. [DOI] [PMID] [PMCID]
13. Xie J, Ding C, Li J, Wang Y, Guo H, Lu Z, et al. Characteristics of patients with coronavirus disease (COVID‐19) confirmed using an IgM‐IgG antibody test. Journal of Medical Virology. 2020;92(10):2004-10. [DOI] [PMID] [PMCID]
14. Jiang S, Hillyer C, Du L. Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses. Trends Immunol 2020;41(5):355-9. [DOI] [PMID] [PMCID]
15. Long Q-X, Liu B-Z, Deng H-J, Wu G-C, Deng K, Chen Y-K, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med 2020;26(6):845-8. [DOI] [PMID]
16. Marklund E, Leach S, Axelsson H, Nyström K, Norder H, Bemark M, et al. Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders. PLoS One. 2020;15(10):e0241104. [DOI] [PMID] [PMCID]
17. Kowitdamrong E, Puthanakit T, Jantarabenjakul W, Prompetchara E, Suchartlikitwong P, Putcharoen O, et al. Antibody responses to SARS-CoV-2 in patients with differing severities of coronavirus disease 2019. PLoS One. 2020;15(10):e0240502. [DOI] [PMID] [PMCID]
18. Sun B, Feng Y, Mo X, Zheng P, Wang Q, Li P, et al. Kinetics of SARS-CoV-2 specific IgM and IgG responses in COVID-19 patients. Emerg Microbes & Infect 2020;9(1):940-8. [DOI] [PMID] [PMCID]
19. Chen Y, Tong X, Li Y, Gu B, Yan J, Liu Y, et al. A comprehensive, longitudinal analysis of humoral responses specific to four recombinant antigens of SARS-CoV-2 in severe and non-severe COVID-19 patients. PLoS Pathog 2020;16(9):e1008796. [DOI] [PMID] [PMCID]
20. Alzaabi AH, Ahmed LA, Rabooy AE, Zaabi AA, Alkaabi M, AlMahmoud F, et al. Longitudinal changes in IgG levels among COVID-19 recovered patients: A prospective cohort study. PLoS One. 2021;16(6):e0251159. [DOI] [PMID] [PMCID]
21. Muecksch F, Wise H, Batchelor B, Squires M, Semple E, Richardson C, et al. Longitudinal serological analysis and neutralizing antibody levels in coronavirus disease 2019 convalescent patients. The Journal of Infectious Diseases. 2021;223(3):389-98. [DOI] [PMID] [PMCID]
22. Wang K, Long Q-X, Deng H-J, Hu J, Gao Q-Z, Zhang G-J, et al. Longitudinal dynamics of the neutralizing antibody response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Clinical Infectious Diseases. 2021;73(3):e531-e9. [DOI] [PMID] [PMCID]
23. Skoog H, Withrow K, Jeyarajan H, Greene B, Batra H, Cox D, et al. Tracheotomy in the SARS‐CoV‐2 pandemic. Head & Neck. 2020;42(7):1392-6. [DOI] [PMID] [PMCID]
24. Wax RS, Christian MD. Practical recommendations for critical care and anesthesiology teams caring for novel coronavirus (2019-nCoV) patients. Canadian Journal of Anesthesia. 2020;67(5):568-76. [DOI] [PMID] [PMCID]
25. Davies NG, Kucharski AJ, Eggo RM, Gimma A, Edmunds WJ, Jombart T, et al. Effects of non-pharmaceutical interventions on COVID-19 cases, deaths, and demand for hospital services in the UK: a modelling study. Lancet. 2020;5(7):e375-e85. [DOI]
26. Ferguson NM, Laydon D, Nedjati-Gilani G, Imai N, Ainslie K, Baguelin M, et al. Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand. Latin American Journal of Pharmacy. 2020;11(4):132-7. [Google Scholar]
27. Woudenberg T, Pelleau S, Anna F, Attia M, Donnadieu F, Gravet A, et al. Humoral immunity to SARS-CoV-2 and seasonal coronaviruses in children and adults in north-eastern France. EBioMed. 2021;70:103495. [DOI] [PMID] [PMCID]
28. Wang X, Guo X, Xin Q, Pan Y, Hu Y, Li J, et al. Neutralizing antibodies responses to SARS-CoV-2 in COVID-19 inpatients and convalescent patients. Clinical Infectious Diseases. 2020;3(62):37-57. [DOI]
29. Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv. 2020;32(8): 20047365.
https://doi.org/10.1101/2020.03.30.20047365 [DOI]
30. Klein SL, Pekosz A, Park H-S, Ursin RL, Shapiro JR, Benner SE, et al. Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. The Journal of Clinical Investigation. 2020;130(11):6141-50. [DOI] [PMID] [PMCID]
31. Carsetti R, Quintarelli C, Quinti I, Mortari EP, Zumla A, Ippolito G, et al. The immune system of children: the key to understanding SARS-CoV-2 susceptibility. Lancet. 2020;4(6):414-6. [DOI] [PMID]
32. Henry C, Zheng N-Y, Huang M, Cabanov A, Rojas KT, Kaur K, et al. Influenza virus vaccination elicits poorly adapted B cell responses in elderly individuals. Cell Host & Microbe. 2019;25(3):357-66. e6. [DOI] [PMID] [PMCID]
33. Arnold KB, Chung AW. Prospects from systems serology research. Immun. 2018;153(3):279-89. [DOI] [PMID] [PMCID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
